New Paradigms in Hypersensitivity Pneumonitis

Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ahluwalia, Bineet [verfasserIn] Singh, Sheetu

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	Hypersensitivity pneumonitis Diagnosis Treatment Radiology

Anmerkung:	© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Übergeordnetes Werk:	Enthalten in: Current respiratory care reports - New York, NY : Springer, 2012, 11(2022), 4 vom: 08. Okt., Seite 116-131
Übergeordnetes Werk:	volume:11 ; year:2022 ; number:4 ; day:08 ; month:10 ; pages:116-131

Links:	Volltext

DOI / URN:	10.1007/s13665-022-00295-5

Katalog-ID:	SPR048812765

Internformat


LEADER	01000caa a22002652 4500
001	SPR048812765
003	DE-627
005	20230519110850.0
007	cr uuu---uuuuu
008	221206s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13665-022-00295-5 \|2 doi
035			\|a (DE-627)SPR048812765
035			\|a (SPR)s13665-022-00295-5-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Ahluwalia, Bineet \|e verfasserin \|4 aut
245	1	0	\|a New Paradigms in Hypersensitivity Pneumonitis
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
520			\|a Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered.
650		4	\|a Hypersensitivity pneumonitis \|7 (dpeaa)DE-He213
650		4	\|a Diagnosis \|7 (dpeaa)DE-He213
650		4	\|a Treatment \|7 (dpeaa)DE-He213
650		4	\|a Radiology \|7 (dpeaa)DE-He213
700	1		\|a Singh, Sheetu \|0 (orcid)0000-0003-3888-9856 \|4 aut
773	0	8	\|i Enthalten in \|t Current respiratory care reports \|d New York, NY : Springer, 2012 \|g 11(2022), 4 vom: 08. Okt., Seite 116-131 \|w (DE-627)718610954 \|w (DE-600)2660484-X \|x 2161-332X \|7 nnns
773	1	8	\|g volume:11 \|g year:2022 \|g number:4 \|g day:08 \|g month:10 \|g pages:116-131
856	4	0	\|u https://dx.doi.org/10.1007/s13665-022-00295-5 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
951			\|a AR
952			\|d 11 \|j 2022 \|e 4 \|b 08 \|c 10 \|h 116-131

Indexfelder

author_variant	b a ba s s ss
matchkey_str	article:2161332X:2022----::eprdgsnyesniiiy
hierarchy_sort_str	2022
publishDate	2022
allfields	10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131
spelling	10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131
allfields_unstemmed	10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131
allfieldsGer	10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131
allfieldsSound	10.1007/s13665-022-00295-5 doi (DE-627)SPR048812765 (SPR)s13665-022-00295-5-e DE-627 ger DE-627 rakwb eng Ahluwalia, Bineet verfasserin aut New Paradigms in Hypersensitivity Pneumonitis 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213 Singh, Sheetu (orcid)0000-0003-3888-9856 aut Enthalten in Current respiratory care reports New York, NY : Springer, 2012 11(2022), 4 vom: 08. Okt., Seite 116-131 (DE-627)718610954 (DE-600)2660484-X 2161-332X nnns volume:11 year:2022 number:4 day:08 month:10 pages:116-131 https://dx.doi.org/10.1007/s13665-022-00295-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 AR 11 2022 4 08 10 116-131
language	English
source	Enthalten in Current respiratory care reports 11(2022), 4 vom: 08. Okt., Seite 116-131 volume:11 year:2022 number:4 day:08 month:10 pages:116-131
sourceStr	Enthalten in Current respiratory care reports 11(2022), 4 vom: 08. Okt., Seite 116-131 volume:11 year:2022 number:4 day:08 month:10 pages:116-131
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Hypersensitivity pneumonitis Diagnosis Treatment Radiology
isfreeaccess_bool	false
container_title	Current respiratory care reports
authorswithroles_txt_mv	Ahluwalia, Bineet @@aut@@ Singh, Sheetu @@aut@@
publishDateDaySort_date	2022-10-08T00:00:00Z
hierarchy_top_id	718610954
id	SPR048812765
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR048812765</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519110850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221206s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13665-022-00295-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR048812765</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13665-022-00295-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ahluwalia, Bineet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Paradigms in Hypersensitivity Pneumonitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypersensitivity pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Singh, Sheetu</subfield><subfield code="0">(orcid)0000-0003-3888-9856</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current respiratory care reports</subfield><subfield code="d">New York, NY : Springer, 2012</subfield><subfield code="g">11(2022), 4 vom: 08. Okt., Seite 116-131</subfield><subfield code="w">(DE-627)718610954</subfield><subfield code="w">(DE-600)2660484-X</subfield><subfield code="x">2161-332X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:4</subfield><subfield code="g">day:08</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:116-131</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13665-022-00295-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">4</subfield><subfield code="b">08</subfield><subfield code="c">10</subfield><subfield code="h">116-131</subfield></datafield></record></collection>
author	Ahluwalia, Bineet
spellingShingle	Ahluwalia, Bineet misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology New Paradigms in Hypersensitivity Pneumonitis
authorStr	Ahluwalia, Bineet
ppnlink_with_tag_str_mv	@@773@@(DE-627)718610954
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2161-332X
topic_title	New Paradigms in Hypersensitivity Pneumonitis Hypersensitivity pneumonitis (dpeaa)DE-He213 Diagnosis (dpeaa)DE-He213 Treatment (dpeaa)DE-He213 Radiology (dpeaa)DE-He213
topic	misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology
topic_unstemmed	misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology
topic_browse	misc Hypersensitivity pneumonitis misc Diagnosis misc Treatment misc Radiology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Current respiratory care reports
hierarchy_parent_id	718610954
hierarchy_top_title	Current respiratory care reports
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)718610954 (DE-600)2660484-X
title	New Paradigms in Hypersensitivity Pneumonitis
ctrlnum	(DE-627)SPR048812765 (SPR)s13665-022-00295-5-e
title_full	New Paradigms in Hypersensitivity Pneumonitis
author_sort	Ahluwalia, Bineet
journal	Current respiratory care reports
journalStr	Current respiratory care reports
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	116
author_browse	Ahluwalia, Bineet Singh, Sheetu
container_volume	11
format_se	Elektronische Aufsätze
author-letter	Ahluwalia, Bineet
doi_str_mv	10.1007/s13665-022-00295-5
normlink	(ORCID)0000-0003-3888-9856
normlink_prefix_str_mv	(orcid)0000-0003-3888-9856
title_sort	new paradigms in hypersensitivity pneumonitis
title_auth	New Paradigms in Hypersensitivity Pneumonitis
abstract	Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
abstractGer	Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
abstract_unstemmed	Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153
container_issue	4
title_short	New Paradigms in Hypersensitivity Pneumonitis
url	https://dx.doi.org/10.1007/s13665-022-00295-5
remote_bool	true
author2	Singh, Sheetu
author2Str	Singh, Sheetu
ppnlink	718610954
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s13665-022-00295-5
up_date	2024-07-03T21:37:58.603Z
_version_	1803595471759867904
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR048812765</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519110850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221206s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13665-022-00295-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR048812765</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13665-022-00295-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ahluwalia, Bineet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Paradigms in Hypersensitivity Pneumonitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP). Recent Findings HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants. Summary The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypersensitivity pneumonitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Singh, Sheetu</subfield><subfield code="0">(orcid)0000-0003-3888-9856</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current respiratory care reports</subfield><subfield code="d">New York, NY : Springer, 2012</subfield><subfield code="g">11(2022), 4 vom: 08. Okt., Seite 116-131</subfield><subfield code="w">(DE-627)718610954</subfield><subfield code="w">(DE-600)2660484-X</subfield><subfield code="x">2161-332X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:4</subfield><subfield code="g">day:08</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:116-131</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13665-022-00295-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">4</subfield><subfield code="b">08</subfield><subfield code="c">10</subfield><subfield code="h">116-131</subfield></datafield></record></collection>
score	7.3996468

Nicht das Richtige dabei?

Schreiben Sie uns!

New Paradigms in Hypersensitivity Pneumonitis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?